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Clinical Efficacy and Complications of Intraocular Lens 
Exchange for Opacified Intraocular Lenses
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Purpose: To evaluate the clinical efficacy and complications of intraocular lens (IOL) exchange.
Methods: A review of medical records was performed for 52 eyes that had undergone an IOL exchange due 
to IOL opacification. Surgical complications and their incidences were analyzed. The mean best corrected 
visual acuity (BCVA) after the IOL exchange was compared with the mean pre-exchange BCVA and with 
the mean BCVA after the initial IOL implantation. Prediction error of refraction and biometric data obtained 
for the IOL exchange were, if available, compared with those obtained for the initial IOL implantation. The 
prediction error for the IOL exchange, calculated from the biometric data obtained before the IOL exchange, 
was compared with that calculated from the measurements obtained before the initial IOL implantation.
Results: The overall complication rates were low and no serious complications were found. The mean BCVA 
improved significantly after the IOL exchange and was not significantly different from that obtained after the 
initial IOL implantation. However, the refractive prediction for the IOL exchange was not as good as it was 
for the initial IOL implantation, which was thought to be related with difficulties in axial length (AL) 
measurements. Biometric data taken before the initial IOL implantation was associated with a significantly 
better refractive prediction than those taken before the IOL exchange.
Conclusions: IOL exchange was both efficacious and safe for visual recovery. However, IOL exchange was 
related with increased difficulty of predicting postoperative refraction; difficulties in AL measurements are the 
suggested cause.
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Implantation of a foldable intraocular lens (IOL) takes an 
essential part of modern cataract surgery. Since SI-18NB 
(AMO
®, USA) was used as the first foldable IOL,
1 there have 
been many changes made in IOL shape and composition to 
improve surgical outcomes and to minimize complications. 
Despite the remarkable improvements in the currently used 
IOLs, there have been discouraging clinical reports regarding 
unexpected late opacification of the implanted IOLs which is 
of concern to both patients and surgeons. Delayed 
opacification of foldable hydrophilic acrylic IOLs is a 
well-known phenomenon. Pathological studies using light 
microscopy, scanning electron microscopy, and X-ray 
spectroscopy have revealed that the opacification was caused 
by granular deposits composed of calcium phosphate 
hydroxide (hydroxyapatite) under the surface of the IOL.
2-4 
Neodymium:YAG (Nd:YAG) laser treatment was used to 
manage this complication by some authors.
5 Although the 
authors attempted to blast the deposits from the IOL with 
laser treatment, the results were disappointing. Nd:YAG laser 
treatment did not remove the deposits or improve vision. 
Meanwhile, several studies have reported that an IOL 
exchange improves vision in such cases.
5-8
In addition to IOL opacification, there are several 
circumstances under which explantation of an IOL, with or 
without implantation of a new IOL, is required as the 
definitive treatment. These circumstances include implantation 
of an IOL with incorrect power, an IOL defect, abnormal 
IOL position, glare symptoms, uveitis glaucoma hyphema 
(UGH) syndrome, and chronic uveitis.
9-11 However, it seems 
that the indications for an IOL exchange are not limited to 
the management of these complicated cases, but may also 
include those patients requiring refractive changes. There are 
already several reports regarding IOL exchange procedures 
performed for patients favoring monovision in whom the 
initial IOL implantation surgeries resulted in similar 
refractive outcome in both eyes and for those who 
experienced unexpected hyperopic or myopic surprises.
9,12 
With further popularization of multifocal IOLs, it seems that SM Kim, et al. INTRAOCULAR LENS EXCHANGE  
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patients who have already undergone a monofocal IOL 
implantation surgery may also be benefited from an IOL 
exchange procedure.
The principal purpose of this study is to evaluate the 
clinical outcome of IOL exchange, including its efficacy in 
visual recovery and its complications. This study also 
provides some insight into the determination of adequate IOL 
power for IOL exchange performed for the eyes with an 
opacified IOL.
Materials and Methods
The present study includes consecutive cases of 52 eyes 
from 48 patients treated with IOL exchange at the Korean 
Veterans hospital between January 2005 and December 2006.
Before the IOL exchange surgery, IOL power was 
calculated using the keratometric value and the axial length 
(AL) obtained either before the initial cataract surgery or 
before the IOL exchange. In 32 cases, reevaluation of 
biometric values was performed using an autokeratore- 
fractometer (Humphrey-Zeiss model 599, USA) and an 
applanation ultrasound (US) A-scanner (Paradigm Medical 
Industries model p37, USA) using the mean pseudophakic 
US velocity of 1533 m/sec in pseudophakic mode. All of the 
IOL measurements for initial IOL implantation taken in our 
hospital were performed by one technician and all of the 
repeat IOL measurements before the IOL exchange were 
done by another technician. The SRK/T formula was used to 
calculate IOL power.
All IOL exchange surgeries were performed by one 
experienced surgeon. Retrobulbar anesthesia using 2% 
lidocaine was used in all cases. After a 1.2 mm-sized clear 
corneal paracentesis incision was made at the temporal side, 
a superior scleral tunnel incision was made with a width of 
approximately 6 mm. The ophthalmic viscoelastic device was 
then introduced into the anterior chamber. A 23 gauge needle 
with a bent tip was used to relieve  adhesion between the 
lens capsule and the opacified IOL. Usually there were firm 
adhesions between the lens capsule and the IOL, and care 
was taken not to exert excessive force. Viscodissection was 
carefully applied to further relieve the adhesions and to safely 
separate the IOL haptics from the lens capsule. In some cases 
in which there were excessively strong adhesions, one or both 
of the haptics had to be cut with Vannas scissors and left 
in the capsular bag to avoid damage to the lens capsules 
and/or the zonules.
5,13 The optic was also sometimes bisected 
before removal. After safely removing the opacified IOL, a 
new foldable posterior chamber IOL was inserted either into 
the capsular bag or into the ciliary sulcus. In all cases in 
which the size of the capsulorhexis opening was smaller than 
the optic size, optic capture with the anterior capsule was 
attempted. Two types of IOLs were used for the exchange 
procedures: Sensar
® (Advanced Medical Optics, USA) and 
Acrysof
® (MA60BM)(Alcon, USA). Finally, the viscoelastic 
device was removed by irrigation and aspiration and the 
scleral wound was closed with interrupted 10-0 nylon sutures.
During postoperative follow-up, visual acuity (VA), 
refraction, and intraocular pressure (IOP) were monitored. 
VAs were evaluated with a standard Snellen chart and 
converted to logMAR for statistical analysis. VA that could 
barely detect a hand movement was defined as 0.001 in 
decimal scale. Refractions were measured by an 
autokeratorefractometer (Humphrey-Zeiss model 599, USA), 
confirmed by subjective refractions, and converted to 
spherical equivalents (SEs) for statistical analysis. 
Postoperative best corrected visual acuity (BCVA) and 
refraction were obtained at least 1 month after each 
operation. The IOP was considered to be elevated when it 
exceeded 21 mmHg or was increased by more than 5 mmHg 
with regard to its preoperative level.
Data collected included age, gender, presence of systemic 
(diabetes mellitus and hypertension) and/or ophthalmic 
comorbidities, interval between initial IOL implantation and 
IOL exchange, site of IOL implantation during the IOL 
exchange, intraoperative complications and execution of 
anterior vitrectomy during the IOL exchange procedure, 
length of postoperative follow-up after the IOL exchange, 
pre- and post-exchange VAs and IOPs, and execution of an 
Nd:YAG posterior capsulotomy after the IOL exchange. 
 The following data were also retrieved when available: 
Type of initial cataract surgery, power and material of the 
initially implanted IOL, site of IOL implantation, biometric 
data used for the IOL calculation (both for the initial and the 
exchange procedures), IOL calculation formula, and the 
BCVA and refractions after the initial IOL implantation.
We analyzed the complications related to the IOL 
exchange and their incidences. The mean BCVA obtained 
after IOL exchange was compared with that recorded before 
IOL exchange and, when available, also with the mean 
BCVA obtained after the initial IOL implantation surgery.
For 32 cases in which the biometric data obtained both 
before the initial IOL implantation surgery and before the 
IOL exchange were available, further analysis was conducted 
regarding the predictability of postoperative refraction. The 
prediction error of postoperative refraction was defined as the 
actual obtained postoperative SE minus the intended SE 
given the implanted IOL power, and its absolute value was 
defined as the absolute error. Cases included in this analysis 
were grouped according to the site of IOL implantation 
during IOL exchange; there was an in-the-bag implantation 
group and an in-the-sulcus group. The refractive results were 
compared between these two groups. Within each group, the 
prediction error for the IOL exchange was then compared 
with the prediction error for the initial IOL implantation 
surgery. The reevaluated keratometric value and AL were 
also compared with the values obtained before the initial IOL 
implantation surgery. The prediction errors of refraction 
which were calculated using these two biometric datasets 
were compared.
Statistical analyses were performed using Microsoft Excel Korean J Ophthalmol Vol.22, No.4, 2008
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and SPSS (version 12.0, SPSS Inc, Chicago, IL). Results 
were considered statistically significant only when the 
p-value was less than 0.05.
Results
Table 1 presents a summary of the total cases. The 
subjects included were 36 men (75%) and 12 women (25%); 
the mean age of the patients was 70.1±7.8 years (range: 
49-84). Four of the male patients had undergone bilateral IOL 
exchanges. Fourteen patients (29.2%) were diabetic and 23 
patients (47.9%) had systemic hypertension. Fifteen eyes 
(31.3%) were from diabetic patients, of which 10 (19.2%) 
had no diabetic retinopathy, 2 (3.9%) had mild 
nonproliferative diabetic retinopathy, and 3 (5.8%) had 
moderate nonproliferative diabetic retinopathy according to 
the early treatment of diabetic retinopathy study (ETDRS) 
criteria.
14 Other ocular comorbidities included glaucoma in 4 
eyes (7.7%), a preexisting superotemporal branch retinal vein 
occlusion in 1 eye (1.9%), and a magnetic resonance 
imaging-proven orbital mass encircling the optic nerve in 1 
eye (1.9%).
The initial procedure was a phacoemulsification surgery in 
49 eyes and an extracapsular cataract extraction in 3 eyes. 
The mean time interval between initial IOL implantation and 
the IOL exchange was 60.4±7.4 months (range: 49.0-81.3) 
and the mean length of follow-up after IOL exchange was 
15.6±11.4 months (range: 1.5-38.5).
During IOL exchange, a new IOL was implanted in the 
bag in 13 eyes (25.0%) and in the sulcus in 39 eyes (75.0%) 
with or without optic capture. Zonular dehiscence occurred 
in 4 eyes (7.7%) and iridodialysis in 1 eye (1.9%). 
Preexisting posterior capsular incompetency was observed in 
4 eyes (7.7%). Seven eyes (13.5%) were treated with 
concomitant anterior vitrectomy. During postoperative 
follow-up, 8 eyes (15.4%) were treated with a Nd:YAG 
posterior capsulotomy because of posterior capsular 
opacification. One eye (case 19) that had developed a delayed 
IOL dislocation associated with severe capsular contracture 
was treated with IOL repositioning by suture fixation to the 
sclera. Aside from case 19, no eye developed serious 
complications such as endophthalmitis, intractable corneal 
decompensation, or retinal detachment. IOP elevation was 
observed in 13 eyes (25%) after 1 week, in 5 eyes (9.6%) 
after 1 month, and was normalized in all cases at the last 
outpatient visit.
The best recorded BCVA after initial IOL implantation 
was available in 51 cases (case 38 was the exception). The 
mean BCVA was 0.90±0.16 (0.06±0.15 logMAR) after initial 
IOL implantation, 0.48±0.16 (0.39±0.41 logMAR) before 
IOL exchange, and 0.88±0.16 (0.07±0.15 logMAR) after IOL 
exchange. A paired t-test revealed that the mean BCVA 
before IOL exchange improved significantly after IOL 
exchange (p<0.001) and it was not significantly different 
from the mean BCVA obtained after the initial IOL 
implantation (p=0.130). There was an increase of nearly 4 
lines in the mean BCVA after IOL exchange.
Table 2 summarizes the results of the analysis on the 
prediction error of postoperative refraction for the IOL 
exchange. In 32 eyes (cases marked with an asterisk (*)), the 
keratometric value and the AL were determined both before 
the initial IOL implantation and before the IOL exchange. 
The mean keratometric values before initial IOL implantation 
and before IOL exchange were 44.20±1.48 diopters (D) and 
44.30±1.51 D, respectively, while the mean ALs were 
23.74±0.75 mm and 23.30±0.82 mm, respectively. A paired 
t-test revealed that the difference between ALs was 
statistically significant (p<0.001), while the difference in the 
mean keratometric values was not significant (p=0.222). A 
mean shortening of the ALs of about 0.43 mm was observed 
before the IOL exchange.
In the group with new IOL implantation in the bag (9 
cases), the mean prediction error and the mean absolute error 
for the initial IOL implantation were -0.04±0.66 D and 
0.56±0.30 D, respectively. The mean prediction error and the 
mean absolute error for the IOL exchange calculated from the 
measurement data taken before the IOL exchange were 
-1.10±1.15 D and 1.18±1.06 D, respectively. The mean 
prediction error and the mean absolute error for the IOL 
exchange using the data taken before the initial IOL 
implantation were -0.26±0.87 and 0.72±0.50 D, respectively. 
The two biometric data resulted in significantly different 
mean prediction errors (p=0.021), indicating significantly 
better refractive prediction with biometric data obtained 
before the initial IOL implantation. The mean ALs before the 
initial IOL implantation and before the IOL exchange were 
23.54±0.61 mm and 23.03±0.56 mm, respectively. The mean 
keratometric values before the initial IOL implantation and 
before the IOL exchange were 44.40±1.67 D and 44.53±1.80 
D, respectively. A Wilcoxon signed rank test showed that the 
difference in mean AL measurements was statistically 
significant (p=0.008), while the difference in mean 
keratometric values was not significant (p=0.440).
For the in-the-sulcus group (23 cases), the mean error and 
the mean absolute error were 0.49±0.72 D and 0.70±0.50 D 
for the initial IOL implantation, -1.18±1.01 D and 1.19±0.99 
D for the IOL exchange using the data taken before the IOL 
exchange, and -0.55±0.92 D and 0.85±0.64 D for the IOL 
exchange using the data taken before the initial IOL 
implantation, respectively. These two biometric data resulted 
in a significantly different mean prediction error for the IOL 
exchange (p=0.004). A better refractive prediction was 
associated with the biometric data obtained before the initial 
IOL implantation. The mean ALs measured before the initial 
IOL implantation and before the IOL exchange were 
23.82±0.80 mm and 23.45±0.88 mm, respectively, while the 
mean keratometric values were 44.13±1.44 D and 44.22±1.42 
D, respectively. A Wilcoxon signed rank test showed that the 
difference in mean AL was significant (p<0.001). In contrast, 
the difference in mean keratometric values was insignificant SM Kim, et al. INTRAOCULAR LENS EXCHANGE  
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Table 1. Summary of cases
Case
Interval
(Mo)
Initial
Op
DMR
grade
Ocular
comorbidities
IOL
Impl.
F/U
(Mo)
BCVA
1
†
BCVA
2
†
BCVA
3
† A-V Z-D I-D
Prev.
PCI
Nd:YAG
P-C
1 57.5 PE PCL - ST BRVO B 10.8  0.1  0.08  0.1 
2 50.1 PE PCL 1 S 37.8  1.0  0.4  1.0  +
3 53.2 PE PCL - Strabismus S 38.5  1.0  0.6  0.8 
4 53.9 PE PCL - B 19.2  1.0  0.7  0.9 
5 49.6 PE PCL - S 27.8  0.8  0.4  0.7 
6 50.1 PE PCL 1 S 29.8  0.9  0.5  1.0  +
7 50.8 PE PCL 4 S 36.5  1.0  0.8  1.0  +
8 49.0 ECCE - S 2.1 0.8  0.6  0.8 
9 57.3 PE PCL 1 S 32.8  1.0  0.8  1.0 
10 56.9 PE PCL 3 B 28.9  1.0  0.6  1.0 
11 * 51.9 PE PCL - S 31.3  0.8  0.7  0.8  A-V Z-D
12 * 56.4 ECCE - B 31.9 0.9  0.5  0.9 A-V +
13 67.5 PE PCL 1 S 2.8  0.9  0.6  0.9 
14 * 53.3 PE PCL - Glaucoma S 18.2  0.9  0.5  0.8 
15 * 53.4 PE PCL - Glaucoma S 18.2  1.0  0.6  0.8 
16 * 49.8 PE PCL - B 6.0  1.0  0.5  0.9  +
17 * 64.7 PE PCL - S 26.7  1.0  0.3  0.9  A-V +
18 * 63.5 PE PCL - Glaucoma S 20.6  0.9  0.3  0.9  Z-D
19 57.6 PE PCL - B 29.1  1.0  0.4  1.0  Z-D
20 * 67.2 PE PCL - S 2.5  1.0  0.3  0.9  A-V +
21 * 62.7 PE PCL 1 S 3.8  1.0  0.5  1.0  +
22 * 54.0 PE PCL - S 2.1  0.9  0.4  0.8 
23 * 53.3 PE  PCL - S 1.5 0.5 0.001 0.7 
24 * 66.7 PE PCL - S 23.4  1.0  0.7  1.0 
25 * 58.3 PE PCL 1 S 24.7  1.0  0.7  1.0 
26 * 60.8 PE PCL 1 S 20.0  1.0  0.5  1.0 
27 * 54.4 PE PCL - S 16.2  1.0  0.7  1.0 
28 * 54.8 PE PCL - Orbital Mass S 12.8  1.0  0.3  1.0 
29 * 63.9 PE PCL - S 4.7  0.7  0.4  0.7  +
30 * 59.7 PE PCL - S 1.9  1.0  0.3  1.0 
31 * 55.1 PE PCL - 　 S 12.1 1.0  0.5  0.9 
32 * 55.9 PE PCL - S 19.6  0.9  0.4  1.0 
33 * 65.3 PE PCL - S 19.1  1.0  0.6  1.0 
34 * 61.3 PE PCL - S 10.3  0.8  0.4  0.8  I-D
35 * 61.5 PE PCL - 　 S 10.3 0.9  0.4  0.8 
36 * 62.7 PE PCL 4 S 14.2  0.7  0.5  0.8 
37 * 61.6 PE PCL - S 26.8  0.9  0.5  0.8 
38 66.9 PE PCL - 　 S2 . 0    ? 0 . 2   0 . 4  
39 * 62.3 PE PCL 3 　 S 25.5 1.0  0.5  1.0 
40 * 62.0 PE PCL - B 10.6  0.8  0.4  0.8  A-V Z-D
41 * 58.6 PE PCL - S 1.6  0.8  0.6  0.8 
42 * 73.2 PE PCL - OHT S 20.3  0.8  0.5  0.7  A-V +
43 * 63.4 PE PCL - B 3.7  0.9  0.7  1.0  +
44 * 61.0 PE PCL - B 2.7  1.0  0.5  1.0 
45 * 64.6 PE PCL - B 18.5  1.0  0.5  1.0 
46 * 70.5 PE PCL 1 B 12.9  1.0  0.3  0.8 
47 * 64.9 ECCE - Glaucoma B 20.9 0.6  0.3  0.6 
48 * 75.8 PE PCL 1 S 5.9  1.0  0.4  1.0  A-V +
49 * 74.8 PE PCL - S 3.1  0.9  0.5  1.0  +
50 * 67.3 PE PCL 1 B 3.2  1.0  0.5  1.0 
51 * 69.3 PE PCL 4 S 1.6  1.0  0.3  1.0 
52 * 81.3 PE PCL - S 2.4  1.0  0.4  1.0 
* Cases included in the analysis of refractive prediction
†  All VA values are in decimal scale.
Mo=months
DMR grade 1=no diabetic retinopathy
DMR grade 3=mild nonproliferative diabetic retinopathy
DMR grade 4=moderate nonproliferative diabetic retinopathy
OHT=ocular hypertension
B=in-the-bag IOL implantation
B-S=in-the-sulcus IOL implantation or optic capture
BCVA 1=BCVA after initial IOL implantation
BCVA 2=BCVA before IOL exchange
BCVA 3=BCVA after IOL exchange
A-V=anterior vitrectomy
Z-D=zonular dehiscence
I-D=iridodialysis
Prev. PCI=previous posterior capsule incompetency identified
Nd:YAG P-C=post-exchange Nd:YAG posterior capsulotomyKorean J Ophthalmol Vol.22, No.4, 2008
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Table 2. Summary of results from analysis of the prediction error of refraction
Group Procedures and data used 
for calculation
Mean axial length 
used*
Mean keratometric 
value used
†
Mean error of
refraction
†
Mean absolute error 
of refraction
†
In-the-bag
IOL implantation group
(n=9)
Initial IOL implantation 23.54±0.61 44.40±1.67 -0.13±0.67 0.58±0.31
IOL exchange,
using secondary 
measurements 
23.03±0.56 44.53±1.80 -1.10±1.15 1.18±1.06
IOL exchange,
using initial measurements 23.54±0.61 44.40±1.67 -0.26±0.87 0.72±0.50
Significance (p-value)
‡ 0.440 0.008 0.021 0.139
In-the-sulcus
or optic capture
IOL implantation group
(n=23)
Initial IOL implantation 23.82±0.80 44.13±1.44 0.47±0.70 0.68±0.49
IOL exchange,
using secondary 
measurements 
23.45±0.88 44.22±1.42 -1.18±1.01 1.19±0.99
IOL exchange,
using initial measurements 23.82±0.80 44.13±1.44 -0.55±0.92 0.85±0.64
Significance (p-value)
‡ 0.464 <0.001 0.004 0.114
* units in millimeters; 
† units in diopters; 
‡ Wilcoxon signed rank test: non-parametric.
(p=0.464).
  
Discussion
There have been a number of clinical reports regarding the 
phenomenon of late postoperative opacification of 
hydrophilic acrylic IOLs.
1-6,15-21 The involved IOLs included 
the Hydroview
® (Bausch & Lomb) and the MemoryLens
® 
(Mentor Ophthalmics, Inc.), which had calcified deposits 
mostly on the optic surface, and the Aqua-sense
® 
(Ophthalmic Innovations International, Inc.), which had 
calcified deposits mostly within the IOL material. 
Furthermore, reports have been published in the Republic of 
Korea regarding late opacification of a hydrophilic acrylic 
IOL, the ACRL-C160
® (Ophthalmed, USA).
1-4 In such cases, 
an IOL exchange procedure may be the definitive treatment 
modality. However, there have been only a few reports 
regarding the surgical outcomes of IOL exchange.
5,13,22,23  The 
principal purpose of this study was to review the clinical 
results, including the efficacy and complications, of IOL 
exchange due to an opacified IOL.
Some authors
4 have suggested that the pathogenic 
mechanism for late opacification of a hydrophilic acrylic IOL 
might be related to a systemic morbidity, such as diabetes 
mellitus. However, in our study, opacification of the IOL was 
readily observed in 37 eyes (71.2%) from non-diabetic subjects.
In our study, the time interval between the initial cataract 
surgery and the IOL exchange was 60.4±7.4 months. A 
previous study1 reported that the development of hydrophilic 
acrylic IOL opacification was observed after 7.8±3.0 months 
in patients with diabetes mellitus and after 14.9±5.8 months 
in those without diabetes. The large discrepancy between the 
previously reported time interval for initiation of IOL 
opacification and the time interval for IOL exchange surgery 
in our study can be explained by the fact that there may have 
been individual differences in the rate of progression of 
opacification and that some patients might have had useful 
vision despite opacification of their IOL. We believe that the 
decision to undergo a second surgery should be made 
deliberately and must take into account all potential risks and 
benefits.
The intraoperative complication rates in our series were at 
least comparable to or relatively lower than those 
demonstrated by previous reports. Yu et al.
5 reported 2 
posterior capsule (PC) ruptures and 3 zonular dehiscences in 
a series of 15 explantation surgeries for calcified IOLs. 
Dagres et al.
22 reported 1 case of PC rupture (4%), 10 cases 
of zonular dehiscence (40%), and 1 case with PC rupture and 
zonular dehiscence (4%) in 25 eyes. Gashau et al.
13 reported 
a 23.1% occurrence rate of vitreous loss necessitating anterior 
vitrectomy. We observed zonular dehiscence in 4 eyes (7.7%) 
and iridodialysis in 1 eye (1.9%). Anterior vitrectomy was 
performed in 7 eyes (13.5%). The lack of vision-threatening 
complications in our study also demonstrates that the IOL 
exchange procedures were performed with sufficient safety.
In our study, the mean BCVA after IOL exchange was 
0.88±0.16 (0.07±0.15 logMAR) and the improvement in 
BCVA was statistically significant (p<0.001) with regard to 
the mean BCVA before IOL exchange, which was 0.48±0.16 
(0.39±0.41 logMAR). Published reports on the mean BCVA 
before and after IOL exchange vary according to the 
surgeons. Dagres et al.
22 reported a BCVA of 0.57±0.24 SM Kim, et al. INTRAOCULAR LENS EXCHANGE  
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(decimal scale) preoperatively and 0.60±0.28 (decimal scale) 
postoperatively at the last follow-up visit. They also 
mentioned that some of the eyes (25%) in their study were 
awaiting Nd:YAG posterior capsulotomy for severe posterior 
capsular opacity at the time of publication. Yu et al.
5 reported 
that the mean BCVA 3 months after the exchange procedure 
was 0.2, which was similar to the VA level (0.25) measured 
3 months after the initial IOL implantation. They explained 
the lower post-exchange VA by mentioning that their cases 
had probably included a high percentage of patients with 
diabetic retinopathy and that the IOL exchange procedures 
were performed primarily to allow more clear visualization 
of their retinas. Jin et al.
9 reported that for posterior chamber 
IOL, the mean pre-exchange BCVA was 0.13±0.15 logMAR 
and the mean post-IOL exchange BCVA was 0.06±0.12 
logMAR. Their series included various indications for IOL 
exchange and was not confined to the management of 
opacified IOLs. 
It would be reasonable to state that the efficacy of IOL 
exchange can be better appreciated by comparing the 
post-exchange BCVA with the best BCVA obtained after the 
initial IOL implantation, rather than by comparing the BCVA 
measured just before the IOL exchange, at which time VA 
would be affected by variable degrees of IOL opacification. 
Our data clearly demonstrated that the mean BCVA after IOL 
exchange was not statistically different from the mean best 
BCVA obtained after initial IOL implantation. Our data also 
showed none had decrease in VA after IOL exchange with 
regard to pre-exchange VA. These  indicate that the IOL 
exchange procedure was not only efficacious in restoring VA, 
but was also safe and tolerable. The type and nature of the 
IOL initially implanted, the type of the initial cataract surgery 
and its complications, the surgical techniques used in the IOL 
exchange, and the experience of the surgeon may be related 
to variable surgical outcomes.
Although we obtained good results with regard to visual 
recovery, the IOL exchange procedure was generally 
associated with a slightly increased difficulty in predicting 
postoperative refraction.
The refractive predictability of the IOL exchange was 
relatively good when a secondary IOL was implanted in the 
bag and when measurement values taken from the initial IOL 
implantation were used to calculate the IOL power. The 
minimal difference between the mean prediction error of 
-0.13±0.67 D after the initial IOL implantation and 
-0.26±0.87 D taken after the IOL exchange for the in-the-bag 
group suggests that the refractive prediction of IOL exchange 
may not be greatly affected if measurement data obtained 
before the initial IOL implantation were of good quality and 
readily available. However, the mean prediction error 
increased to -1.10±1.15 D when the biometric data obtained 
just before the IOL exchange were used.
Compared to the in-the-bag group, there was a slightly 
larger myopic shift in the mean postoperative refraction for 
the in-the-sulcus group. The mean prediction error of 
0.49±0.70 D obtained after the initial IOL implantation and 
-0.55±0.92 D obtained after the IOL exchange using the same 
biometric data taken before the initial IOL implantation imply 
that a mean refractive shift of about -1.04 D occurred. This 
shift can be partially explained by the more anterior 
positioning of the new IOLs with regard to the capsular 
bag.
24,25 In our study, the power of the new IOL was adjusted 
by an amount ranging from -0.5 to -1.0 D if the IOL was 
to be implanted in the sulcus. Also, for the in-the-sulcus 
group, the biometric data obtained just before the IOL 
exchange were associated with increased prediction errors 
resulting in a mean prediction error of -1.18 D, indicating 
additional deterioration of the mean postoperative refraction 
by -0.63 D. Regardless of the site of IOL implantation for 
the IOL exchange, the biometric data taken just before the 
IOL exchange were associated with increased prediction 
errors of refraction.
Statistical analyses comparing the biometric data obtained 
before the initial IOL implantation surgery and those obtained 
just before the IOL exchange revealed that there was no 
significant difference in the mean keratometric values, but 
there was a significant difference in the mean ALs. This 
suggests that the keratometric change, which was assumed to 
be induced by the initial cataract surgery, was actually 
negligible and the change in the ALs was the major factor 
responsible for the decreased refractive predictability. In our 
study, the mean AL measured just before the IOL exchange 
was approximately 0.3-0.4 mm shorter; this was thought to 
be related to difficulties in taking AL measurements using an 
US A-scan in eyes with opacified IOLs. 
Kora et al.
26 reported that mean corneal refractive powers 
were not statistically different before and after cataract 
surgery, but that the ALs were markedly different in some 
cases. They noted that it was difficult to determine the 
appropriate AL for the IOL exchange. They calculated the 
ALs retrospectively using the Holladay or SRK/T formula, 
and reported that the calculated ALs were much longer than 
the values that were measured directly. Many eyes in their 
series had become myopic after the initial IOL implantation, 
which implies that the initially measured ALs might have 
been slightly shorter. The authors concluded that even after 
correcting the AL and A-constant, they could not achieve 
precise refractive prediction for the IOL exchange. They 
suggested that other factors probably contributed to the 
increased error in IOL power determination.
The US AL biometry measures the time needed for an 
ultrasonic wave to travel through the cornea, anterior 
chamber, lens, and vitreous. To calculate the distance that the 
ultrasound traveled, the velocity must be known. Different 
ocular components have different US velocities, so accurate 
measurement of the AL requires that US velocities are 
properly assumed for these tissues. Table 3 shows the US 
velocities used by several authors.
27-30 According to Holladay 
and Prager,
31,32 the actual pseudophakic AL can be expressed 
using the following equation:Korean J Ophthalmol Vol.22, No.4, 2008
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Table 3. US velocities used by various authors for various ocular tissues and IOL materials at body temperature (35-37°C)
Authors Holladay JT
27 Lowery MD and et al.
28 Lee and Choi
29 Hoffer KJ
30
Cornea
Aqueous, vitreous
Crystalline lens
PMMA IOL
Silicone IOL
Acrylic IOL
1640 m/sec
1532 m/sec
-
2780 m/sec
980 m/sec
2180 m/sec
-
-
-
2718 m/sec
980 m/sec
1900 m/sec
-
1532 m/sec
1641 m/sec
2718 m/sec
980 m/sec
2200 m/sec
1641 m/sec
1532 m/sec
1641 m/sec
2690 m/sec
980 m/sec
-
1532 1532 
IOL
1532
AL = ALM + LT(1- ) ALM + CALF
V
=
where AL=actual pseudophakic AL, ALM1532=AL 
measured at 1532 m/sec, LT=center thickness of the IOL, 
VIOL=US velocity of the IOL material, and CALF=corrected 
AL factor. The center thickness of an IOL is variable 
according to the manufacturer's design and the diopteric 
powers, both of which are not always available to the 
surgeon performing the IOL exchange. Assuming an acrylic 
IOL with an US velocity of 2180 m/sec and a central 
thickness of 0.7-1.0 mm, a CALF of 0.207-0.297 mm is 
obtained. An US velocity of 2200 m/sec, as used by Lee and 
Choi,
29 yields a CALF of 0.212-0.303 mm. This potential 
variability in the CALF may partly explain the mean 
shortening of the AL observed just before IOL exchange. A 
limitation of this approach is that the material and/or central 
thickness of an opacified IOL are not always available in 
clinical practice. There are also concerns regarding the extent 
to which the AL measurement may be affected by various 
degrees of opacification.
The standard deviations (intercase variability) of the 
prediction errors were generally greater in the IOL exchange 
group compared with the initial IOL implantation group and 
were slightly larger for the in-the-sulcus group than for the 
in-the-bag group. Altered optical properties of the opacified 
IOLs and a US velocity that was not adequate for IOLs with 
various degrees of opacification may be related to the 
increase in the mean and standard deviation of the prediction 
errors. Operator-related errors could have also been 
responsible, because each pair of AL measurements was 
performed by different technicians. Increased variability in 
the actual postoperative positioning of the IOL with regard 
to the initial IOL implantation surgery may also have been 
responsible. Jin et al.
9 reported their experience with IOL 
exchange due to incorrect lens power and suggested that the 
refractive surprise after cataract surgery could be attributed 
to inherent errors in the biometry and formula, which may 
not be appropriate for certain eyes. Their observation may 
also provide some explanation for the increased prediction 
errors related to IOL exchange in our study. However, our 
data suggest that if the biometric data obtained before IOL 
exchange are available and of good quality, IOL exchange 
with implantation of a new IOL in a more stable position 
(in-the-bag position) may be associated with a sufficiently 
small amount of prediction error of refraction.
To our knowledge, this is the first clinical report from the 
Republic of Korea regarding the clinical efficacy and 
complications of the IOL exchange procedure for an 
opacified IOL. Our data showed excellent visual recovery 
results and good results with regard to complications. 
Although the predictability of the postoperative refraction of 
the IOL exchange was relatively good using biometric data 
obtained before the initial cataract surgery and employing a 
new IOL implantation in-the-bag, we faced difficulties with 
the refractive predictions calculated using biometric 
measurements obtained just before the IOL exchange. 
Difficulties in making the AL measurement in eyes with an 
opacified IOL was the most probable cause. Although our 
study was limited by a relatively small number of cases, our 
experience suggests that good quality initial biometric data 
and new IOL implantation in the bag can produce good 
postoperative refractive results. Use of an US velocity 
appropriate for the IOL is also likely to result in improved 
refractive prediction. We believe that an IOL exchange 
procedure should be performed only after comprehensive 
informed consent is given by the patient. Dagres et al.
22 
mentioned that various symptoms and complaints reported by 
patients with opacified IOLs did not correlate well with their 
VAs and that VA alone was not a good criterion for 
performing an IOL exchange. The surgeon must be deliberate 
in making decisions regarding whether or not an IOL 
exchange surgery should be performed for an eye with an 
opacified IOL.
IOL exchange surgery is the only effective treatment for 
patients with an opacified IOL. However, indications for IOL 
exchange are no longer limited to complications following 
IOL implantation and they are becoming even larger due to 
the increasing refractive demands of patients previously 
treated with IOL implantation. It would be worthwhile for 
ophthalmologists to become familiar with the procedures, 
efficacies, limitations, and complications associated with IOL 
exchange. We hope that further studies with a larger group 
of patients and proper stratification may help provide 
solutions to the problems that we encountered with IOL 
exchange.
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